RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $32

Moomoo NewsApr 4 00:32 ET · Ratings

Express News | Intellia Begins Phase 3 Trial for CRISPR Gene Therapy Targeting Rare Nerve Disease

BenzingaApr 3 07:35 ET

Express News | Intellia Therapeutics Inc: Plans to Submit a Biologics Licensing Application for Attrv-Pn by 2028

ReutersApr 3 07:34 ET

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (Nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis With Polyneuropathy

Globe NewswireApr 3 07:30 ET

RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk

MT NewswiresApr 3 07:16 ET · Ratings

$NTLA Stock Is up 11% Today. Here's What We See in Our Data.

Quiver QuantitativeApr 2 11:31 ET